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Abstract
Themolecular effects of obesity are mediated by alterations in the levels of adipocytokines. High leptin level associated
with obese state is a major cause of breast cancer progression and metastasis, whereas adiponectin is considered a
“guardian angel adipocytokine” for its protective role against various obesity-related pathogenesis including breast
cancer. In the present study, investigating the role of adiponectin as a potential inhibitor of leptin, we show that
adiponectin treatment inhibits leptin-induced clonogenicity and anchorage-independent growth. Leptin-stimulated
migration and invasion of breast cancer cells is also effectively inhibited by adiponectin. Analyses of the underlying
molecular mechanisms reveal that adiponectin suppresses activation of two canonical signaling molecules of leptin
signaling axis: extracellular signal-regulated kinase (ERK) and Akt. Pretreatment of breast cancer cells with adiponectin
protects against leptin-induced activation of ERK and Akt. Adiponectin increases expression and activity of the physiolog-
ical inhibitor of leptin signaling, protein tyrosine phosphatase 1B (PTP1B), which is found to be integral to leptin-antagonist
function of adiponectin. Inhibition of PTP1B blocks adiponectin-mediated inhibition of leptin-induced breast cancer
growth. Our in vivo studies show that adenovirus-mediated adiponectin treatment substantially reduces leptin-induced
mammary tumorigenesis in nudemice. Exploring therapeutic strategies, we demonstrate that treatment of breast cancer
cells with rosiglitazone results in increased adiponectin expression and inhibition of migration and invasion. Rosiglitazone
treatment also inhibits leptin-induced growth of breast cancer cells. Taken together, these data show that adiponectin
treatment can inhibit the oncogenic actions of leptin through blocking its downstream signaling molecules and raising
adiponectin levels could be a rational therapeutic strategy for breast carcinoma in obese patientswith high leptin levels.
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Introduction
A vast number of epidemiological studies suggest that obesity is a
pandemic condition that greatly influences risk, prognosis, and pro-
gression of various cancers such as colon, prostate, endometrium,
hepatocellular, and breast. Investigating the relationship of obesity with
mortality from breast cancer, many studies show that obese women in
the highest quintile of body mass index have double the death rate from
breast cancer when compared with women in the lowest quintile [1–4],
hence providing one of the few preventive interventions capable of
making a significant effect on associated disease conditions. Obesity
is associated with an increase in number and size of adipocytes that
greatly alters the local and systemic secretion of biologically active
polypeptides, adipocytokines such as leptin and adiponectin. Acting
by endocrine, paracrine, and autocrine mechanisms, adipocytokines
affect various biologic processes [5,6].
Several epidemiological studies have linked high levels of plasma
leptin with increased risk and poor prognosis for breast carcinogenesis
[7–11]. Circulating as a 16-kD protein, partially bound to plasma pro-
teins, leptin exerts its biologic actions through specific cell surface
receptors [leptin receptors (LRs)] present in a variety of tissues [12].
Breast carcinoma cells express higher levels of leptin and LR in com-
parison to normal mammary epithelial cells. In fact, overexpression
of leptin is observed in 92% of breast tumors and LRs are overexpressed
in 83% breast tumors, whereas no or very low expression of leptin and
LRs is found in normal mammary epithelial cells [13]. Using loss-of-
function mutants for leptin and LR, in vivo studies show that leptin or
LR-deficient mouse mammary tumor virus (MMTV)–transforming
growth factor–α mice do not develop oncogene-induced mammary
tumors [14,15], hence providing direct evidence for the involvement
of leptin in breast carcinogenesis. Hypothalamic LR-reconstituted
db/db (LR-null) mice [16] crossed with MMTV-PyMT mice exhibit
that LR-mediated signaling promotes breast carcinogenesis [17]. In ad-
dition, diet-induced obese MMTV–transforming growth factor–αmice
show higher levels of leptin as well as increased breast tumor growth
[18]. Xenografts of MMTV-Wnt1 tumors grow faster in diet-induced
obese mice in comparison with lean counterparts and exhibit stunted
growth when transplanted in leptin-deficient (Ob/Ob) mice [19]. In
recent years, many laboratories including ours have shown that leptin
increases proliferation of breast, endometrial, hepatocellular, and many
other cancer cells through multiple signaling pathways including Stat3/
extracellular signal-regulated kinase (ERK)/Akt signaling [20–30]. Our
recent research has shown the direct stimulatory effect of leptin on breast
cancer cell migration, invasion, and epithelial-mesenchymal transition
(EMT) [20,21,24]. The therapeutic potential of inhibition of leptin
has been evaluated to some extent in diseases associated with metabolic
syndrome [31,32], but the importance of inhibition of leptin signaling
in carcinogenesis is still elusive and is an active area of research.
Adiponectin (also known as ACRP30, apM1, adipoQ, and GBP28)
[33–36], first identified in the mid-1990s, is an important adipo-
cytokine that is known for its protective role against obesity-related dis-
orders and the metabolic syndrome, particularly in the pathogenesis of
type 2 diabetes and cardiovascular disease [37–39]. Multiple functions
of adiponectin include suppression of proliferation and activation of
immune cells, down-regulation of vascular adhesion molecules in
endothelial cells, and inhibition of smooth muscle migration [40].
Adiponectin is reported to directly bind certain growth factors to con-
trol their bioavailability [41]. Cellular functions of adiponectin are
mainly mediated through two adiponectin receptors, AdipoR1 and
AdipoR2 [42]. Recently, T-cadherin has also been identified as AdipoR
[43]. Combination of interactions between adiponectin and its recep-
tors mediate the cellular functions of adiponectin in a tissue-dependent
manner. Several recent studies evaluated and established a role for
adiponectin in carcinogenesis [44–46]. Epidemiological evidences have
put forth an inverse connection between obesity-associated low plasma
levels of adiponectin with incidence as well as progression of many
common forms of cancer [47,48]. Low-serum adiponectin levels are
associated with increased risk of breast cancer in both postmenopausal
and premenopausal women, independent of age, menopause status,
hormone receptor status, lymph node metastasis, and status of estrogen
receptor (ER) and Her2/neu. It is also suggested that tumors arising in
patients with low-serum adiponectin levels may have a more aggressive
phenotype (large size of tumor, high histologic grade, and increased
metastasis) [47,48]. Providing molecular evidence, several recent studies
show adiponectin-mediated antiproliferative response in breast cancer
cells [49–53]. Investigating upstream regulatory nodes capable of orches-
trating the downstream signaling axes of adiponectin, we recently show
that adiponectin inhibits metastatic properties of breast cancer through
activation of master upstream kinase and tumor suppressor, LKB1 [54].
In the present study, we specifically investigated if adiponectin
can inhibit the oncogenic actions of leptin. Intriguingly, we found
that adiponectin inhibits the effect of leptin on malignant properties
of cancer cells including migration and invasion and also inhibits im-
portant downstream molecules of leptin signaling while activating
physiological inhibitor of leptin signaling. In agreement with our
in vitro data, we found that adiponectin treatment inhibits leptin-
induced breast tumorigenesis in vivo. Thus, raising adiponectin might
be an attractive goal for breast cancer prevention and therapy, par-
ticularly for patients with hyperleptinemic condition. Using thiazoli-
dinedione drugs to raise adiponectin levels, we provide evidence that
rosiglitazone treatment is capable of inhibiting leptin-induced migra-
tion and invasion of breast cancer cells.
Materials and Methods
Antibodies
Antibodies for phosphorylated Akt (pAkt), Akt, phosphorylated
ERK (pERK), ERK, phosphorylated Stat3 (pStat3), Stat3, phosphor-
ylated AMPK (pAMPK), 5′ adenosine monophosphate-activated
protein kinase (AMPK), and LKB1 were purchased from Cell Signaling
Technology (Danvers, MA). Anti–protein tyrosine phosphatase 1B
(PTP1B) antibody (Ab) was procured from BD Biosciences (San Jose,
CA). Ab for β-actin was purchased from Sigma-Aldrich (St Louis, MO).
Cell Culture, Reagents, and Treatments
The human breast cancer cell lines MCF-7, T47D, MDA-MB-231,
and MDA-MB-468 were obtained from the American Type Culture
Collection (Manassas, VA) and maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS (Gemini
Bioproducts, Woodland, CA) and 2 μM L-glutamine (Invitrogen,
Carlsbad, CA). Cell line authentication was done by analysis of known
genetic markers or response (e.g., expression of estrogen receptor and
p53 and estrogen responsiveness) [21,24]. For treatment, cells were
seeded at a density of 1 × 106 per 100-mm tissue culture dish. After
24 hours of serum starvation, the culture media were changed to serum-
free media containing treatments as indicated. Cultures were treated
with human recombinant leptin (Sigma-Aldrich) at 100 ng/ml [24]
and/or human recombinant full-length adiponectin (Biovendor,
Candler, NC) at 10 μg/ml for indicated durations [54]. PTP1B
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inhibitor PR-129 (6-methyl-2-(oxalylamino)-4, 5, 6, 7-tetrahydrothieno
[2, 3-c] pyridine-3-carboxylic acid trifluoroacetic acid salt) was procured
from Enzo Life Sciences (Famingdale, NY). Rosiglitazone was pur-
chased from Cayman Chemical Company (Ann Arbor, MI). Clinical
studies examining the effect of rosiglitazone therapy in women with
breast cancer showed that rosiglitazone at 8 mg yields a maximum serum
concentration (Cmax ± SD) of 598 ± 117 mg/ml or 1.67 μmol/l and is
well tolerated [55,56]. This concentration is within the 1 to 10 μmol/l
range used to induce antiproliferative effects on mammary epithelial
cells in vitro [57,58]. Additionally, higher doses of rosiglitazone have
also been used in vitro [59,60]. We examined the effect of various
concentrations of rosiglitazone in this study.
Clonogenicity Assay
To perform colony formation assay, we plated breast cancer cells
(single-cell suspension) in 12-well plates at a density of 250 cells per well
overnight [21]. The following day, cells were treated with 100 ng/ml
human recombinant full-length leptin and 10 μg/ml human recombi-
nant full-length adiponectin alone or in combination, and the medium
was replaced with fresh medium containing treatments every 3 days.
After a 10-day treatment period, the medium was removed and colo-
nies were stained with crystal violet (0.1% in 20% methanol). Colony
numbers were assessed visually and colonies containing >50 normal-
appearing cells were counted. Pictures were taken using a digital camera.
Anchorage-Independent Growth Assay
Anchorage-independent growth of breast cancer cells was assayed
by colony formation in soft agar [21]. Briefly, equal volumes of
agar (1.2%) and complete medium were mixed to make 0.6% agar
growth medium solution in six-well tissue culture plates. Cells (2 ×
103 cells/well) were suspended in media with or without treatment
followed by mixing with equal volume of agar (0.6%). Cell suspen-
sion agar mix (2 ml) was then added to each well. Plates were incu-
bated at 37°C with 5% CO2 in a humidified incubator for 3 weeks,
and media with or without treatment were added every 3 days. Col-
onies were stained with 0.005% crystal violet in phosphate-buffered
saline (PBS) for 1 hour at room temperature and observed using
Olympus IX50 inverted microscope. Colonies were counted in five
randomly selected fields at 10× magnification. Results are expressed
as average number of colonies counted per microfield.
Migration Assay
To perform migration assays [24,26], we plated cells into the
24-well cell culture plate, precoated with human fibronectin (5 μg/cm2;
Sigma, St Louis, MO). Cells were allowed to grow in DMEM contain-
ing 10% FBS to confluence and then were washed with serum-free
medium and serum starved for 16 hours. A 1-mm-wide scratch was
made across the cell layer using a sterile pipette tip. After washing with
serum-free medium twice, DMEM containing 10 μg/ml human fibro-
nectin was added to replace matrix depleted with the cells. Plates were
photographed immediately after scratching. Cells were treated with hu-
man recombinant leptin at 100 ng/ml and/or adiponectin at 10 μg/ml
alone and in combination. Plates were photographed after 24 and
48 hours at the identical location of the initial image.
Tumor Cell Invasion Assay
For an in vitro model system for metastasis, a matrigel invasion
assay was performed by using a Matrigel invasion chamber from
BD Biocoat Cellware (San Jose, CA) [24]. Cells were seeded at a den-
sity of 1 × 105 cells per insert and cultured overnight. After 16 hours
of serum starvation, the culture media were changed to serum-free
media containing treatments as indicated. Triplicate wells were used
for each treatment. Cells were treated with human recombinant
leptin at 100 ng/ml and/or adiponectin at 10 μg/ml alone and in
combination. After 24-hour incubation, cells remaining above the
insert membrane were removed by gentle scraping with a sterile cotton
swab. Cells that had invaded through the matrigel to the bottom of the
insert were fixed in methanol for 10 minutes. After being washed in
PBS, the cells were stained with hematoxylin-eosin. The inserts were
subsequently washed in PBS and briefly air-dried and mounted. The
slides were coded to prevent counting bias, and the number of invaded
cells on representative sections of each membrane were counted with a
light microscope. The number of invaded cells for each experimental
sample represents the average of triplicate wells.
Western Blot
Whole-cell lysates were prepared by scraping cells in 250 μl of ice-
cold modified RIPA buffer [50 mM Tris-Cl (pH 7.4), 150 mMNaCl,
1 mM EDTA, 1% NP-40, 0.25% Na deoxycholate, 1 mM PMSF,
10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM Na3VO4, and 1 mM
NaF] [26]. The lysate was rotated 360° for 1 hour at 4°C followed
by centrifugation at 12,000g for 10 minutes at 4°C to clear the cellular
debris. Proteins were quantified using the Bradford Protein Assay Kit
(Bio-Rad, Hercules, CA). Equal amounts of proteins were resolved on
sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis
(PAGE) and transferred to nitrocellulose membranes, andWestern blot
analyses were performed using the previously described antibodies.
Immunodetection was performed using enhanced chemiluminescence
(ECL System; Amersham Pharmacia Biotech Inc, Arlington Heights, IL)
according to manufacturer’s instructions.
Mitogen-Activated Protein Kinase and Akt Activity Assay
Mitogen-activated protein kinase (MAPK) and Akt were immuno-
precipitated with the specific antibodies following our previously pub-
lished immunoprecipitation procedure [24]. For immunoprecipitation,
whole-cell lysate from breast cancer cells was incubated with specific
antibodies for ERK and Akt and the mixture was rotated slowly at
4°C for 16 hours. A total of 20 μl of packed protein A/G agarose beads
was added, and the mixture was incubated at 4°C for 1 hour with ro-
tation. The beads were collected by gentle centrifugation and washed
twice with 1.5 ml of ice-cold buffer [50 mM Tris-Cl (pH 7.4), 150 mM
NaCl, 1 mM EDTA, 1% NP-40, 0.25% Na deoxycholate, 1 mM
PMSF, 10 μg/ml aprotinin, and 10 μg/ml leupeptin]. After the final
wash, the precipitated protein-bead complexes were resuspended in
elution buffer. MAPK and Akt activities were measured using MAPK
Activity Assay Kit (Chemicon International, Temecula, CA) and Akt
Activity Assay Kit (Calbiochem, EMD Millipore, Billerica, MA)
following the manufacturers’ instructions.
PTP1B Activity Assay
Breast cancer cells were treated with 10 μg/ml adiponectin alone
or in combination with 50 μM PTP1B inhibitor PR-129 for 2 hours.
PTP1B activity assay was performed using PTP1BAssay Kit (Calbiochem)
following manufacturer’s instructions. Purified PTP1B and Suramin
inhibitor available in the assay kit were used as positive and negative
controls, respectively.
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RNA Isolation and Reverse Transcription–Polymerase
Chain Reaction
Reverse transcription–polymerase chain reaction (RT-PCR) analysis
was performed following previously published protocol [21], using spe-
cific primers for adiponectin. Total cellular RNA was extracted using
the TRIzol Reagent Kit (Life Technologies, Inc, Rockville, MD) and
quantified by UV absorption. RT-PCR was carried out using specific
sense and antisense PCR primers for amplification. PCR products were
resolved by 2% agarose gel electrophoresis and visualized by ethidium
bromide staining.
Breast Tumorigenesis Assay
MDA-MB-231 (5 × 106) cells in 0.1 ml of Hank’s balanced salt
solution were injected subcutaneously into the right gluteal region of
4- to 6-week-old female athymic nude mice [21], procured from
Harlan Laboratories Inc (Indianapolis, IN). Two weeks after initial
implantation, animals were grouped in five experimental groups
(eight mice per group). Animals were treated with intratumoral injec-
tions of 1) recombinant adenovirus [108 plaque-forming units (pfu)]
expressing adiponectin (Ad-Adn) or 2) luciferase (Ad-Luc) (kind gift
fromDr YuWang, Assistant Professor of Pharmacology and Pharmacy,
University of Hong Kong) [53] or 3) saline or 4) intraperitoneal injec-
tions of leptin (dosage of 5 mg/kg) [21] or 5) leptin and Ad-Adn to-
gether, every 36 hours for the duration of the experiment. Tumors were
measured using digital vernier calipers, with tumor volume calculated
using the formula (V = a/2 × b2), where V is the tumor volume in cubic
millimeters and a and b are the largest and smallest diameters in milli-
meters, respectively. All animals were sacrificed after 4 weeks of treatment.
Tumors were collected, weighed, fixed in 10% neutral-buffered formalin,
and subjected to further analysis byWestern and immunohistochemistry.
All animal studies were in accordance with the guidelines of Emory
University, Institutional Animal Care and Use Committee (IACUC).
Statistical Analysis
All experiments were independently performed three times in tripli-
cates. Statistical analysis was done using Microsoft Excel software. Sig-
nificant differences were analyzed using Student’s t test and two-tailed
distribution. Data were considered to be statistically significant if P <
.001. Data are expressed as means ± SE between triplicate experiments.
For animal studies, analysis of variance with repeated measurements
was carried out to compare the mean tumor volume between the five
different groups. The overall P value for testing for differences between
at least two groups is <.0001.
Results
Adiponectin Inhibits Leptin-Induced Malignant Properties
of Breast Cancer Cells
Mounting epidemiological and clinical evidence has put forth the
role of adipocytokines on the center stage to explain the molecular
connection between obesity and carcinogenesis. Recently, we and
others have shown that leptin increases proliferation and growth of
breast, endometrial, and hepatocellular cancers through activation of
multiple downstream signaling pathways [20–30]. However, low
adiponectin levels are significantly associated with an increased tumor
growth and metastasis [44,47,48,61,62] indicating an anti-oncogenic
role for adiponectin. We have recently shown that adiponectin inhib-
its growth and migration potential of breast cancer cells [54]. Here,
we specifically examined if adiponectin can inhibit the pro-cancerous
actions of leptin using various breast cancer cell lines. We found that
adiponectin not only inhibited anchorage-dependent and anchorage-
independent growth of breast cancer cells alone, but it also prevailed
over the stimulatory effects of leptin. Adiponectin decreased leptin-
induced clonogenicity and soft-agar colony formation of MCF7 and
MDA-MB-231 breast cancer cells (Figure 1, A and B). MCF10A cells
are nontumorigenic in athymic nude mice and have been used exten-
sively as representative normal mammary epithelial cells. Adiponectin
treatment did not inhibit growth ofMCF10A cells, whereas leptin elicit
a slight increase in clonogenicity (Figure W1). Cancer progression is a
multistep process that involves invasion of basement membrane by
tumor cells and migration to points far from a given primary tumor
mass leading to metastasis [63]. We examined the effect of adiponectin
treatment on leptin-induced invasion andmigration properties of breast
carcinoma cells using matrigel invasion and scratch migration assays. As
expected, leptin increased migration of breast carcinoma cells, whereas
adiponectin inhibited migration in a conventional scratch migration
assay. Importantly, adiponectin treatment inhibited migration of
MCF7, T47D, MDA-MB-231, and MDA-MB-468 breast cancer cells
in the presence of leptin overcoming its strong pro-migratory potential
(Figure 1C ). Next, we performed matrigel invasion assay to examine
the effect of adiponectin on leptin-induced invasion potential of breast
carcinoma cells. As evident from Figure 1D, leptin treatment increased
invasion of cancer cells through matrigel in comparison to untreated
cells, whereas adiponectin treatment inhibited invasion of breast cancer
(MCF7 and MDA-MB-231) cells. Leptin-mediated increased invasion
of cancer cells was effectively inhibited by adiponectin (Figure 1D).
Collectively, these results show that adiponectin treatment can effec-
tively inhibit leptin-induced clonogenicity, anchorage-independent
three-dimensional (3D) colony formation, and migration and invasion
of breast cancer cells.
Adiponectin Inhibits Phosphorylation of Key Components
of Leptin Signaling in Breast Cancer Cells
Binding of leptin to the LR (Ob-Rb) results in phosphorylation of
conserved tyrosine residues [64], and these phosphorylation events are
important for subsequent signaling events including Janus kinase
(JAK) and Stat3 activation [64]. Canonical downstream signaling of
leptin involves activation of phosphatidylinositol 3-kinase/Akt and
ERK signaling [24,26]. Our previous studies have shown the direct
involvement of JAK/Stat3, phosphatidylinositol 3-kinase/Akt, and
ERK signaling in pro-cancerous actions of leptin [25,27]. We sought
to determine the underlying molecular mechanism by which adipo-
nectin treatment inhibits oncogenic actions of leptin. Leptin increased
phosphorylation of Ser473 on Akt and Thr202 and Tyr204 on p42 ERK
and p44 ERK within 15 to 30 minutes after leptin treatment, which
remain elevated for the course of the experiment, whereas no change
was observed in total protein levels (Figure 2A). An increase in ERK
and Akt activity was also observed within 30 minutes of leptin treatment
(Figure 2C). However, adiponectin treatment inhibited phosphoryla-
tion of Akt and ERK (Figure 2B) as well as Akt and ERK activity
(Figure 2D). To examine the antagonistic effect of adiponectin on leptin-
induced phosphorylation of Akt and ERK, we pretreated breast cancer
cells with adiponectin for 24 hours followed by leptin treatment for
various intervals of time. Pretreatment with adiponectin rendered breast
cancer cells largely unresponsive to stimulatory effects of leptin showing
that adiponectin pretreatment could protect cells against the oncogenic
actions of leptin. Leptin failed to increase Akt and ERK phosphoryla-
tion (Figure 3A) as well as Akt and ERK activity (Figure 3, C and D)
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Figure 1. Adiponectin reduces the stimulatory effect of leptin on clonogenicity, anchorage-independent growth migration and invasion
potential of breast carcinoma cells. (A) Breast cancer cells (MCF7 and MDA-MB-231) were treated with 100 ng/ml leptin (L) and 10 μg/ml
adiponectin (Adn) alone and in combination (L+ Adn) and subjected to clonogenicity assay. Colonies containing>50 normal-appearing cells
were counted. Adiponectin inhibited leptin-induced clonogenicity. (B) Breast cancer cells were subjected to soft-agar colony formation
assay in the presence of leptin (L) and/or adiponectin (Adn) as in A for 3 weeks. Results are expressed as average number of colonies
counted (in six microfields). *P < .005, compared with untreated controls; **P < .001, compared with untreated controls; #P < .005,
compared with L treatment. Adiponectin inhibited leptin-induced anchorage-independent growth. (C) Breast cancer (MCF7, T47D,
MDA-MB-231, and MDA-MB-468) cells were subjected to scratch migration assay in the presence of leptin and adiponectin treatments as
described in A. The histogram shows the fold change in migration. *P < .01 and **P < .005, compared to untreated controls; #P < 0.01,
compared to leptin (L)–treated cells. Adiponectin inhibited migration of breast cancer cells even in the presence of leptin. (D) MCF7 and
MDA-MB-231 cells were cultured inMatrigel invasion chambers followed by treatment as in A for 24 hours. The number of cells that invaded
through thematrigel was counted in five different regions. The slides were blinded to remove counting bias. The result showsmean of three
independent experiments performed in triplicates. *P < .005, compared with untreated controls; #P < .001, compared to leptin-treated
cells. Adiponectin treatment significantly reduced leptin-induced matrigel invasion.
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in adiponectin-pretreated breast cancer cells. In a reverse experiment,
cells were pretreated with leptin followed by adiponectin treatment
for various intervals of time. Adiponectin treatment successfully inhib-
ited leptin-induced phosphorylation of Akt and ERK (Figure 3B), ex-
hibiting that adiponectin treatment could override the biologic effects
of leptin.
Adiponectin Modulates an Important Modifier of
Leptin Signaling, PTP1B
Probing the hierarchy of leptin signaling events, we previously
showed that activation of JAK/Stat is upstream of the activation of
ERK and Akt molecules [25,27]. Leptin signaling can be inhibited
by two main inhibitory molecules: the suppressor of cytokine signal-
ing 3 (SOCS3) and PTP1B [65,66]. SOCS proteins contain a central
Src Homology 2 (SH2) domain, which allows these proteins to inhibit
signaling by binding to phosphorylated JAK proteins or through direct
interaction with tyrosine phosphorylated receptors. Overexpression of
SOCS3 inhibits leptin-mediated tyrosine phosphorylation of JAK2 and
subsequently Stat3 activation [65]. PTP1B is another significant down-
stream regulator of leptin signal transduction [66] that recognizes a spe-
cific substrate motif within JAK2. Overexpression of PTP1B decreases
phosphorylation of JAK2 and blocks leptin signaling. We hypothesized
that adiponectin may inhibit leptin signaling by upregulating these
physiological inhibitors of leptin signaling. Therefore, we examined
the effect of adiponectin treatment on the expression of PTP1B in
breast cancer cells. Employing Western blot analysis, we found
that adiponectin treatment significantly increased PTP1B expression
in breast cancer cells (Figure 4A). Adiponectin treatment increased
PTP1B protein expression within 15 minutes after treatment in MCF7
and within 30 minutes to 1 hour in MDA-MB-468 breast cancer
cells. Next, we examined the modulation of PTP1B activity in re-
sponse to adiponectin treatment. Adiponectin treatment significantly
increased PTP1B activity, whereas PTP1B inhibitor PR-129 (6-methyl-
2-(oxalylamino)-4, 5, 6, 7-tetrahydrothieno [2, 3-c] pyridine-3-carboxylic
acid trifluoroacetic acid salt) effectively inhibited PTP1B activity. Com-
bined treatment with PR-129 and adiponectin showed a reduction in
adiponectin-induced PTP1B activity (Figure 4B). Purified PTP1B and
Suramin were used as positive and negative controls for PTP1B activ-
ity assay. To investigate whether PTP1B plays a critical role in leptin-
antagonist function of adiponectin, we treated breast cancer cells with
adiponectin alone and in combination with PTP1B inhibitor followed
by examination of phosphorylation status of Stat3, a key node of leptin-
signaling network [24,25]. Adiponectin treatment reduced phosphory-
lation of Stat3 in breast cancer cells. Showing importance of PTP1B in
leptin-antagonist function of adiponectin, PR-129 treatment inhibited
adiponectin-mediated inhibition of Stat3 phosphorylation (Figure 4C).
These findings suggest an important mechanistic link by which
adiponectin can block leptin signaling through modulating the levels
of physiological upstream inhibitor, PTP1B.
PTP1B Plays an Important Role in Leptin-Antagonist
Function of Adiponectin
Our studies showed that PR-129 could inhibit PTP1B activity
and reversed adiponectin-mediated inhibition of key leptin-signaling
events (Figure 4). Next, we investigated the importance of PTP1B in
adiponectin-mediated inhibition of leptin-induced malignant prop-
erties of breast cancer cells. Breast cancer cells were treated with
adiponectin and PR-129 in combination with leptin and subjected
to clonogenicity, anchorage-independent 3D colony formation, and
migration assay. Inhibition of clonogenicity observed on adiponectin
Figure 2. Evidence of adiponectin-mediated inhibition of leptin signaling in breast cancer cells. (A) Breast cancer cells were treated with
100 ng/ml leptin (L) for various intervals of time. (B) Breast cancer cells were treated with 10 μg/ml adiponectin (Adn) for various intervals
of time. Total protein was isolated and equal amounts of proteins were resolved by SDS-PAGE and subjected to immunoblot analysis
using antibodies for pERK and pAkt. The membranes were reblotted using total ERK and Akt antibody. Anti-actin antibody was used as a
control. The blots are representative of multiple independent experiments. MDA-MB-231 cells were treated with leptin (C) or adiponectin
(D) for various intervals of time and subjected to ERK and Akt activity assay. Leptin increases phosphorylation and activity of ERK and
Akt. *P < .005, compared with untreated controls. Adiponectin treatment inhibited phosphorylation and activity of ERK and Akt.
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treatment was reversed in the presence of PR-129 (Figure 5A). Adi-
ponectin treatment inhibited leptin-induced anchorage-independent
colony formation of MCF7 and MDA-MB-231 cells. Combined
treatment with PR-129 effectively reduced inhibitory effect of
adiponectin, resulting in an increase in number of leptin-induced
3D colonies formed (Figure 5B). As observed earlier, adiponectin in-
hibited leptin-induced migration of both MCF7 and MDA-MB-231
breast cancer cells. Importantly, combined treatment with PTP1B in-
hibitor abrogated adiponectin-mediated inhibition of leptin-induced
migration of breast cancer cells (Figure 5C ). These results showed the
importance of PTP1B in leptin-antagonist function of adiponectin, as
inhibition of PTP1B activity clearly blocked adiponectin’s inhibitory
effect on leptin function.
Adiponectin Inhibits Leptin-Induced Breast Tumor
Progression in Athymic Nude Mice
We investigated the physiological relevance of our in vitro findings
by evaluating whether adiponectin has any suppressive effects on
leptin-induced development of breast tumorigenesis in vivo. Leptin
treatment significantly increased tumor growth as compared to the
vehicle-treated group. Adiponectin treatment using adenovirus-Adn
inhibited tumor growth resulting in reduced tumor size compared to
vehicle and adenovirus-luciferase control. Importantly, adiponectin
treatment efficiently inhibited leptin-induced breast tumor growth
(Figure 6A). Previous studies from our laboratory showed adiponectin-
mediated activation of the LKB1–AMPK-S6K axis in breast cancer
cells [54]. Adiponectin adenovirus–treated breast cancer cells show
Figure 3. Adiponectin inhibits key nodes of leptin signaling in breast cancer cells. (A) Breast cancer cells were pretreated with 10 μg/ml
adiponectin (Adn) for 24 hours followed by 100 ng/ml leptin (L) treatment for various intervals of time. (B) Breast cancer cells were
pretreated with 100 ng/ml leptin (L) followed by 10 μg/ml adiponectin (Adn) treatment for various intervals of time. Total protein was
isolated and equal amounts of proteins were resolved by SDS-PAGE and subjected to immunoblot analysis using antibodies for pERK
and pAkt. The membranes were reblotted using total ERK and Akt antibody. Anti-actin antibody was used as a control. The blots are
representative of multiple independent experiments. Adiponectin treatment decreased leptin-induced phosphorylation of ERK and Akt in
breast cancer cells. (C, D) Breast cancer cells were pretreated with 10 μg/ml adiponectin (Adn) for 24 hours followed by 100 ng/ml leptin
(Lpn) treatment for various intervals of time and subjected to ERK and Akt activity assay. Adiponectin pretreatment decreased leptin-
induced Akt and ERK activity.
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elevated LKB1 levels indicating functionally active adiponectin
(Figure W2). Adiponectin adenovirus–treated tumors showed elevated
levels of adiponectin, whereas leptin-treated tumors showed increased
staining for leptin as compared to control group (Figure 6B). The
immunohistochemical assessment of tumor proliferation showed higher
MIB1 (Ki-67 receptor) and phosphohistone H3 expression in leptin-
treated group, whereas low to none MIB1 and phosphohistone H3
expression was observed in adiponectin-treated group (data not shown).
Figure 4. Adiponectin increases PTP1B expression in breast cancer cells. (A) Breast cancer cells MCF7 and MDA-MB-468 were treated
with 10 μg/ml adiponectin (Adn) for various intervals of time as indicated. Untreated cells are denoted as 0. Total protein was isolated
and equal amounts of proteins were resolved by SDS-PAGE and subjected to immunoblot analysis using specific antibodies for PTP1B.
The blots are representative of multiple independent experiments. Adiponectin treatment increased PTP1B expression in MCF7 and
MDA-MB-468 breast cancer cells. The histogram is the mean of densitometric analysis showing relative density units (RDUs) of the
Western blot signals for PTP1B normalized to actin in multiple experiments. *P < .005, compared with untreated controls. (B) Breast
cancer cells were treated with 10 μg/ml adiponectin (Adn) and 50 μM of PR-129 (Inh.) alone or in combination (Adn + Inh.). Purified
lysates were subjected to PTP1B activity assay. Purified PTP1B and Suramin were used as positive and negative controls, respectively.
Adiponectin treatment increases PTP1B activity. (C) MCF7 cells were treated with 10 μg/ml adiponectin (Adn) and 50 μM of PR-129 (Inh.)
alone or in combination (Adn + Inh.). Total protein was isolated and equal amounts of proteins were resolved by SDS-PAGE and sub-
jected to immunoblot analysis using specific antibodies for pStat3 and Stat3. The blots are representative of multiple independent
experiments. Actin was used as control. Adiponectin decreased pStat3, whereas PTP1B inhibitor abrogates adiponectin’s effect.
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Figure 5. Inhibition of PTP1B reduces adiponectin’s inhibitory effects on clonogenicity and anchorage-independent growth of breast
carcinoma cells. (A) Breast cancer cells (MCF7 and MDA-MB-231) were treated with adiponectin (Adn) and PR-129 alone (Inh.) and in
combination (Adn + Inh.) and subjected to clonogenicity assay. Colonies containing >50 normal-appearing cells were counted. PR-129
inhibited adiponectin’s inhibitory effect on clonogenicity. (B) Breast cancer cells were subjected to soft-agar colony formation assay in
the presence of leptin, adiponectin + leptin, and adiponectin + leptin + PR-129 (Inh.) for 3 weeks. Results are expressed as average
number of colonies counted (in five microfields). *P < .005, compared with leptin-treated cells; #P < .01, compared to adiponectin +
leptin–treated cells. PR-129 abrogates adiponectin-mediated inhibition of leptin-induced anchorage-independent growth. (C) Breast cancer
cells were grown to confluence, scratched with a pipette tip, and photographed immediately following scratching (0 hour). Culture media
were replaced with media containing 100 ng/ml leptin, leptin + 10 μg/ml adiponectin (Adn), and leptin + adiponectin + 50 μMPR-129 (Inh.).
The plates were photographed at the identical location of the initial image (0 hour) at 24 and 48 hours. The results shown are representative
of three independent experiments performed in triplicates. PR-129 inhibits adiponectin’s effect on leptin-induced migration of breast cancer
cells. The histogram shows the fold change in migration. *P < .01, compared to leptin-treated cells; #P < .01, compared to leptin +
adiponectin–treated cells. All the experiments were performed thrice in triplicates.
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We previously reported that adiponectin activates phosphorylation of
AMPK, which is an important marker of biologic activity of adiponectin
[54]. Here, we examined if adiponectin treatment using adenovirus-
Adn increased AMPK phosphorylation, hence showing activation of
adiponectin signaling. Adenovirus-adiponectin–treated tumors exhibited
increased phosphorylation of AMPK in comparison to adenovirus-
luciferase–treated tumors. These results confirmed that adenovirus-
adiponectin treatment elevated adiponectin signaling in breast tumors.
These results collectively show that adiponectin inhibits oncogenic
actions of leptin including migration and invasion of breast cancer cells
and inhibits components of the signaling machinery used by leptin
while up-regulating an important upstream inhibitor, PTP1B.
Figure 6. Adiponectin treatment inhibits leptin-induced breast tumor growth in nude mice. MDA-MB-231 cell–derived tumors were
developed in nude mice and treated with leptin (L), vehicle (V), control-adenoviral (Ad-Luc), adiponectin-adenoviral (Ad-Adn; 108 pfu),
and L + Ad-Adn. (A) Tumor growth was monitored by measuring the tumor volume for 6 weeks (n = 8 mice per group). Ad-Adn treat-
ment reduced tumor size as compared to Ad-Luc, *P < .01. Adiponectin treatment significantly reduced leptin-induced tumor size as
compared to leptin alone (P < .01) and Ad-luc (P < .01). (B) Tumor samples were subjected to immunohistochemical analysis using
leptin and adiponectin antibody. Ad-Adn–treated tumors showed significant increase in adiponectin expression as compared to Ad-Luc–
treated tumors, *P < .05 Ad-Adn versus Ad-Luc. Leptin-treated tumors showed significant increase in leptin expression as compared to
Ad-luc, *P < .05 leptin versus Ad-Adn. (C) Tumor lysates were subjected to immunoblot analysis using pAMPK, AMPK, and actin anti-
bodies. Adiponectin-treated tumors showed increased phosphorylation of AMPK showing increased adiponectin signaling.
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Rosiglitazone Increases Adiponectin Expression and Inhibits
Oncogenic Effects of Leptin on Breast Cancer Cells
In conjunction with higher levels of leptin, obese state is associated
with decreased levels of adiponectin. Our studies show that adiponectin
acts as a leptin antagonist through modulating PTP1B, a physiological
inhibitor of leptin signaling, resulting in inhibition of key nodes of
leptin-signaling network. We hypothesize that therapeutic intervention
capable of modulating adiponectin levels may prove effective in inhib-
iting leptin-induced breast cancer growth and metastatic potential.
Thiazolidinediones, synthetic ligands for the transcription factor perox-
isome proliferator–activated receptor-γ, were reported to increase serum
adiponectin levels [67,68]. Several peroxisome proliferator–activated
receptor-γ ligands are already in clinical use for the treatment of type
2 diabetes [69]. Different concentrations of each of these ligands (piogli-
tazone, troglitazone, and rosiglitazone) were tested for their effect on
adiponectin expression in breast cancer cells (data not shown). Breast
cancer cells were treated with various concentrations ranging from 1
to 100 μM rosiglitazone and subjected to clonogenicity (Figures 7A
and W3A) and anchorage-independent growth assay (Figure W3B).
Dose-dependent and statistically significant inhibition of clonogenicity
and soft-agar colony formation was observed in the presence of rosigli-
tazone. Treatment with 10 μM rosiglitazone resulted in ∼50% to
60% inhibition in clonogenicity and soft-agar colony formation, whereas
higher concentrations (25, 50, and 100 μM) were more inhibitory.
MCF10A and MCF12A cells were treated with various concentra-
tions of rosiglitazone ranging from 5 to 100 μM in an anchorage-
dependent growth assay. We found that MCF10A and MCF12A were
significantly more resistant to the growth inhibition by rosiglitazone
compared with MDA-MB-231 and MCF7 cells. For example, survival
of MDA-MB-231 cells was decreased by∼50% in 10 μM rosiglitazone,
whereas growth of MCF10A and MCF12A remains unaffected by the
similar treatment (Figure W4). These results indicate that the human
breast cancer cells are significantly more sensitive to growth suppression
by rosiglitazone compared with a normal mammary epithelial cell line.
Selectivity toward cancer cells is highly desirable in potential cancer
preventive and therapeutic agents. With invasion and migration being
two important processes in cancer progression, we examined the effect
of rosiglitazone on breast cancer cell migration and invasion by using
scratch migration and matrigel invasion assays. Rosiglitazone treatment
(as low as 2 μM) resulted in inhibition of migration of breast cancer
cells (Figure 7B) in comparison with untreated cells. As evident from
Figure 7C , low doses of rosiglitazone treatment decreased invasion of
breast cancer cells through matrigel compared to untreated cells. Next,
we determined the effect of rosiglitazone on adiponectin expression.
Western blot and RT-PCR analyses showed that rosiglitazone stim-
ulated expression of adiponectin in MDA-MB-231 and MDA-MB-
468 cells within 15 minutes after treatment with a significant increase
after 1 hour of treatment as compared to untreated cells (Figure 7, D
and E ). Adiponectin activates phosphorylation of AMPK in breast
cancer cells [51,54]. Next, we examined AMPK phosphorylation levels
upon rosiglitazone treatment. Rosiglitazone treatment led to increased
phosphorylation of AMPK inMCF7,MDA-MB-231, andMDA-MB-
468 cells within 15 minutes after treatment, whereas no change in total
AMPK protein expression level was observed (Figures 7F and W5). To
test our hypothesis that therapeutic intervention capable of increasing
adiponectin levels in breast cancer cells may prove effective in inhibiting
leptin-induced growth and metastatic potential, breast cancer cells were
treated with a combination of rosiglitazone and leptin followed by anal-
ysis of clonogenic potential and anchorage-independent 3D colony
growth. Rosiglitazone treatment not only inhibited anchorage-dependent
and independent growth as expected, but it also effectively inhibited
leptin-induced clonogenicity and soft-agar colony formation (Figure 8,
A and B). Collectively, these results provide in vitro as well as in vivo
evidence that adiponectin treatment can inhibit the oncogenic actions
of leptin in breast cancer cells and suggest the involvement of PTP1B in
blocking key nodes of leptin signaling and using rosiglitazone could be
a rational therapeutic strategy for breast carcinoma in obese patients
with high leptin levels.
Discussion
With epithelial and other cells accounting for only approximately 10%
of human breast volume, adipocytes are the most predominant cell type
in breast tumor microenvironment. Close positioning between breast
tumor cells and adipocytes owing to reduction in separating connective
tissue, invasion of carcinoma cells through the basement membrane
leading to infiltration of fibrous tissue barriers allows increased para-
crine cross talk. Adipocytes are active endocrine cells that secrete various
biologically active adipocytokines, providing a potential molecular
mechanism linking obesity and carcinogenesis [64]. Since obesity is a
hyperleptinemic and hypoadiponectinemic state, in the present study,
we investigated the effect of physiological levels of adiponectin on
oncogenic effects of leptin. The following novel findings are described
in this study: 1) adiponectin treatment inhibits malignant properties such
as clonogenicity, anchorage-independent 3D colony formation, and in-
vasion and migration of breast carcinoma cells; 2) adiponectin blocks
oncogenic effects of leptin by inhibiting leptin-induced malignant prop-
erties; 3) adiponectin treatment inhibits key molecules of leptin signal-
ing; 4) adiponectin treatment leads to overexpression of PTP1B, which
is an upstream physiological inhibitor of leptin signaling; 5) adiponectin
treatment inhibits leptin-induced breast tumorigenesis in vivo; 6) rosigli-
tazone increases adiponectin expression and inhibits oncogenic effects of
leptin on breast cancer cells. These results show that adiponectin treat-
ment significantly inhibits leptin-induced malignant properties of breast
carcinoma cells and inhibits activation of key molecules of leptin signaling;
thus, using adiponectin analogs or augmentation of its levels or activity
may be a suitable therapeutic strategy for metastatic breast carcinoma.
Obese breast cancer patients exhibit a higher risk for lymph node
metastasis, larger tumor burden, and mortality when compared with
nonobese breast cancer patients [1,70] irrespective of the estrogen
receptor status. Our studies along with others have clearly shown that
leptin induces proliferation, migration, and invasion of breast carcinoma
cells; hence, strategies blocking leptin activity might prove useful for
breast cancer patients with elevated leptin levels. Biologic effects of lep-
tin are mediated through active LRs; therefore, neutralization of leptin
activity can be achieved with soluble LRs that bind free leptin in the
circulation, leptin antagonists that bind LRs leading to their inacti-
vation, and specific anti-LR monoclonal Abs (mAbs) that bind to the
receptor preventing leptin signaling or antibodies developed against
leptin. Anti-LR mAbs exhibit a long half-life in the circulation and
good affinity for the receptor, but these mouse-generated mAbs need
to be humanized to eliminate their potential immunogenicity. Another
approach to target LR is presented by the development of recombinant,
monomeric nanobodies. Nanobodies block leptin-induced conforma-
tional change of LR without interfering with the leptin-LR interaction.
Nanobodies do not cross the blood-brain barrier; hence, they can selec-
tively inhibit peripheral activity of leptin. Importantly, recent develop-
ment of Allo-aca, a nine–amino acid–long peptide analog of LR
binding site III of leptin, presents new possibilities of research and
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therapeutic strategy. Allo-aca and LR antagonists not only suppress
the growth of established breast tumors in vivo but also inhibit leptin-
induced angiogenesis, leptin-induced inflammatory signal transduction
events, and autoimmunity-derived inflammation [32,71].
While all these agents to counteract leptin signaling are in various stages
of development, we decided to investigate the potential antagonistic
effect of protective adipocytokine adiponectin on leptin-induced onco-
genic activities in breast carcinoma. Most of the adipocytokines are
casually linked to obesity-related diseases, whereas adiponectin has shown
promising insulin-sensitizing, anti-inflammatory, and anti-atherogenic
activities. Adiponectin levels are decreased in obesity and various obesity-
related diseases. The clinical relevance of adiponectin treatment has
been suggested by studies showing that treatment with adiponectin can
improve glucose/lipid homeostasis, increase insulin sensitivity, and pre-
vent atherosclerosis in animal models [44,72,73]. Raising adiponectin
level thus becomes an attractive goal for breast cancer therapeutics as
well as prevention. Epidemiological data report that thiazolidinedione
use is associated with reduced cancer risk [74] and rosiglitazone, a
thiazolidinedione, increases plasma adiponectin levels in overweight
women with polycystic ovary syndrome (PCOS) [75], subjects with
Figure 7. Rosiglitazone increases adiponectin expression, modulates adiponectin signaling molecule, inhibits clonogenicity and migration
and invasion of breast cancer cells. (A) Breast cancer cells (MCF7 and MDA-MB-231) were treated with various concentrations of rosiglita-
zone and subjected to clonogenicity assay. Colonies containing >50 normal-appearing cells were counted. Rosiglitazone inhibited clono-
genic potential of breast cancer cells. (B) MDA-MB-231 cells were subjected to scratch migration assay in the presence of rosiglitazone
treatments as indicated. Plates were photographed immediately after scratching, 20 and 44 hours after rosiglitazone treatment at the iden-
tical location of the initial image. Rosiglitazone inhibited migration of breast cancer cells. (C) MDA-MB-231 cells were cultured in Matrigel
invasion chambers followed by rosiglitazone treatment as indicated. The number of cells that invaded through the matrigel was counted in
five different regions. The slides were blinded to remove counting bias. *P < .005, compared with untreated controls. Rosiglitazone treat-
ment significantly reduced matrigel invasion potential of breast cancer cells. Representative images of cells invaded through matrigel are
shown. Breast cancer cells (MDA-MB-231 andMDA-MB-468) were treatedwith 50 μMrosiglitazone for various intervals of time as indicated.
Untreated cells are denoted as 0. (D) Total RNA was isolated followed by RT-PCR to analyze the expression of adiponectin using specific
primer sets. (E) Total protein was isolated and equal amounts of proteinswere resolved by SDS-PAGE and subjected to immunoblot analysis
using specific antibodies for adiponectin. The blots are representative of multiple independent experiments. Rosiglitazone treatment in-
creases adiponectin expression in MDA-MB-231 and MDA-MB-468 breast cancer cells. (F) MCF7 and MDA-MB-231 cells were treated with
rosiglitazone as in D. Total protein was isolated and equal amounts of proteins were resolved by SDS-PAGE and subjected to immunoblot
analysis using specific antibodies for pAMPK and AMPK. Actin was used as control.
Figure 8. Rosiglitazone reduces the stimulatory effect of leptin on clonogenicity and anchorage-independent growth of breast carci-
noma cells. (A) Breast cancer cells (MCF7 and MDA-MB-231) were treated with 100 ng/ml leptin (L) and 50 μM rosiglitazone (Rosi) alone
and in combination (L + Rosi) and subjected to clonogenicity assay. Colonies containing >50 normal-appearing cells were counted.
Rosiglitazone inhibited leptin-induced clonogenicity. (B) Breast cancer cells were subjected to soft-agar colony formation assay in the
presence of leptin (L) and/or rosiglitazone (Rosi) as in A for 3 weeks. Results are expressed as average number of colonies counted (in
six microfields). *P < .005, compared with untreated controls; **P < .001, compared with untreated controls; #P < .005, compared
with L treatment. Rosiglitazone inhibited leptin-induced anchorage-independent growth.
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type 2 diabetes mellitus and with impaired glucose tolerance [76]. Our
study showed that rosiglitazone treatment increased adiponectin levels in
breast cancer cells and induced the activation of adiponectin-signaling
network. Of interest, rosiglitazone treatment also inhibited leptin-
induced clonogenicity and growth of breast cancer cells. It is interesting
to note that some anti-diabetic drugs (e.g., metformin) and bioactive mol-
ecules (e.g., honokiol) can partially mimic adiponectin action and induce
AMPK signaling in cancer cells [77,78]. Mouse models of caloric restric-
tion and wheel running/exercise exhibit increase in adiponectin levels and
protection against breast carcinogenesis [79,80], indicating alternative
approaches to modulate adiponectin and its biologic effects. Preclinical
development of adiponectin-based peptide compounds acting as
AdipoR agonists presents another approach for adiponectin-based
therapeutics. Identification of minimal adiponectin active site followed
by development of pharmacologically improved analogs led to the devel-
opment of ADP 355 as an optimal AdipoR agonist effectively inhibiting
growth of AdipoR-positive breast cancer cells (MCF7, MDA-MB-231)
and modulating adiponectin-signaling network [81]. In addition to in-
creasing adiponectin levels using adiponectin analogs, modulating
AdipoR activity, augmentation of its effectiveness [82], can potentially
become a future beneficial treatment for breast carcinoma patients.
Collectively, this study underscores the importance of adipocytokine
levels, as they impact breast carcinogenesis and also provide mechanistic
insight. Considering the high prevalence of obesity in the United States,
novel therapeutic strategies to modulate leptin/adiponectin levels have
the potential to significantly impact the vast majority of obese breast
carcinoma patients and improving overall prognosis.
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Figure W1. Adiponectin and leptin treatments do not modulate
growth of MCF10A cells in a significant manner. MCF10A cells
were treated with 100 ng/ml leptin (L) and 10 μg/ml adiponectin
(Adn) alone and in combination (L + Adn) and subjected to clono-
genicity assay. Colonies containing >50 normal-appearing cells
were counted. Adiponectin did not modulate growth of MCF10A
in a significant manner.
Figure W2. Adenovirus-adiponectin (Ad-Adn) treatment increases
expression of LKB1 in breast cancer cells. MDA-MB-231 cells were
treated with Ad-luc (luciferase control) or Ad-Adn (108 pfu) for
various time intervals as indicated. Total protein was isolated and
equal amounts of proteins were resolved by SDS-PAGE and sub-
jected to immunoblot analysis using specific antibodies for LKB1.
The blots are representative of multiple independent experiments.
Ad-Adn treatment increases LKB1 expression in MDA-MB-231
breast cancer cells.
Figure W3. Rosiglitazone inhibits clonogenicity and soft-agar growth of breast cancer cells. (A) Breast cancer cells (MDA-MB-468 and
T47D) were treated with various concentrations of rosiglitazone as indicated and subjected to clonogenicity assay. Untreated control
cells are denoted as control. Colonies containing >50 normal-appearing cells were counted. Rosiglitazone inhibited clonogenic potential
of breast cancer cells. (B) Breast cancer cells (MCF7, MDA-MB-231, and T47D) were treated with various concentrations of rosiglitazone
as indicated and subjected to soft-agar 3D colony formation assay. Results are expressed as average number of colonies counted (in
six microfields). *P < .005, compared with untreated controls. Rosiglitazone inhibited anchorage-independent growth of breast
cancer cells.
Figure W4. Rosiglitazone do not modulate growth of MCF10A and MCF12A cells in a significant manner. MCF10A and MCF12A cells
were treated with various concentrations of rosiglitazone as indicated and subjected to clonogenicity assay. Untreated control cells are
denoted as control. Colonies containing >50 normal-appearing cells were counted. Rosiglitazone did not modulate growth of MCF10A
and MCF12A cells significantly.
Figure W5. Rosiglitazone increases phosphorylation of AMPK
in breast cancer cells. Breast cancer cells (MDA-MB-468) were
treated with 50 μM rosiglitazone for various intervals of time as
indicated. Untreated cells are denoted as 0. Total protein was iso-
lated and equal amounts of proteins were resolved by SDS-PAGE
and subjected to immunoblot analysis using specific antibodies
for pAMPK. The blots are representative of multiple independent
experiments. Rosiglitazone treatment increases phosphorylation
of AMPK in MDA-MB-468 breast cancer cells.
